Cargando…
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the Db-Ig platform, which...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993124/ https://www.ncbi.nlm.nih.gov/pubmed/33752566 http://dx.doi.org/10.1080/19420862.2021.1902034 |